Kulchavenya E V, Neimark A I, Tsukanov A Yu, Neimark A B, Razdorskaya M V
FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia, Novosibirsk, Russia.
Scientific Chief of the Medical Center Avicenna of the group of companies Mother and Child, Novosibirsk, Russia.
Urologiia. 2023 Jul(3):34-41.
Chronic cystitis predominates in the structure of urinary tract infections (UTIs). International guidelines are mainly focused on the treatment of acute uncomplicated cystitis; the approaches for managing patients with chronic cystitis has not been sufficiently developed.
A total of 91 patients were included in prospective multicenter randomized comparative controlled study. They were divided into three groups. In the group 1, 32 women received only standard antibiotic therapy for 5 days. In the group 2, 28 patients (received standard therapy plus rectal suppositories Superlymph 25 IU 1 time per day for 10 days). In the main group, 31 women received standard therapy in combination with the use of rectal suppositories Superlymph at a dose of 10 IU 1 time per day for 20 days. Standard antibiotic therapy included fosfomycin trometamol 3.0 g once and furazidin 100 mg three times for 5 days. To assess the long-term results, patients were invited for a follow-up 6 months after the end of therapy.
To determine the long-term results of combined etiologic and pathogenetic therapy, including Superlymph rectal suppositories at a dose of 10 U and 25 U, in patients with chronic cystitis.
Six months later, 82/91 (90.1%) women were examined to assess the long-term results. At 6 months, in group 1 a relapse of the cystitis developed in 17 women (60.7%) after an average of 67.3+/-9.4 days. In group 2, recurrence was observed in 12 patients (44.4%), and the relapse-free period was longer, averaging of 84.3+/-9.2 days. The best results were demonstrated in the main group, in which the relapse-free period lasted an average of 123.5+/-8.7 days, and a relapse developed in only 8 cases (29.6%). In 19 patients (70.4%) there were no symptoms after six months. Differences between groups were highly significant (p<0.001). In all groups, none of the patients had more than one recurrence of the cystitis during the follow-up.
Combined antibiotic therapy results in the absence of recurrence within six months in 39.3% of patients with chronic cystitis. Complex etiologic and pathogenetic therapy, including Superlymph rectal suppositories, allows to significantly reduce the number of recurrences and prolong the relapse-free period. Among the patients who received a course of local cytokine therapy at a dose of 25 units for 10 days, 55.6% did not have a recurrence of chronic cystitis within 6 months. In the group of patients who, along with etiologic therapy, received Superlymph rectal suppositories at a dose of 10 IU for 20 days, a relapse was absent in 70.4% of patients.
慢性膀胱炎在尿路感染(UTIs)结构中占主导地位。国际指南主要侧重于急性单纯性膀胱炎的治疗;慢性膀胱炎患者的管理方法尚未充分发展。
共有91例患者纳入前瞻性多中心随机对照研究。他们被分为三组。在第1组中,32名女性仅接受了5天的标准抗生素治疗。在第2组中,28名患者(接受标准治疗加直肠栓剂Superlymph 25 IU,每天1次,共10天)。在主要组中,31名女性接受标准治疗并联合使用剂量为10 IU的直肠栓剂Superlymph,每天1次,共20天。标准抗生素治疗包括磷霉素氨丁三醇3.0 g一次和呋喃西林100 mg三次,共5天。为评估长期结果,在治疗结束后6个月邀请患者进行随访。
确定联合病因和发病机制治疗(包括剂量为10 U和25 U的Superlymph直肠栓剂)对慢性膀胱炎患者的长期结果。
6个月后,对82/91(90.1%)名女性进行了检查以评估长期结果。在6个月时,第1组中17名女性(60.7%)在平均67.3±9.4天后发生膀胱炎复发。在第2组中,12名患者(44.4%)出现复发,无复发期更长,平均为84.3±9.2天。主要组显示出最佳结果,其中无复发期平均持续123.5±8.7天,仅8例(29.6%)发生复发。19名患者(70.4%)在6个月后无症状。组间差异高度显著(p<0.001)。在所有组中,随访期间没有患者膀胱炎复发超过一次。
联合抗生素治疗使39.3%的慢性膀胱炎患者在6个月内无复发。包括Superlymph直肠栓剂在内的复杂病因和发病机制治疗可显著减少复发次数并延长无复发期。在接受25单位剂量局部细胞因子治疗10天疗程的患者中,55.6%在6个月内慢性膀胱炎未复发。在病因治疗的同时接受10 IU剂量Superlymph直肠栓剂治疗20天的患者组中,70.4%的患者无复发。